Lundbeck

The study will combine cognitive assessments with genetic data and survey responses to gain insights into the causes of these two mental health conditions.

Dutch gene therapy firm UniQure and academic collaborators have been awarded a three-year grant worth €2.5 million ($3.2 million) from the European Commission to develop a treatment for Huntington’s disease that combines RNAi and gene replacement.

Participating vendors are being asked to build fully functional platforms for next-generation sequence data storage and analysis.

Although Lundbeck's foray into the RNAi drugs scene is modest compared with investments made by other pharmas, it comes at a time when many of those firms have put the brakes on their commitment to the approach.

While a handful of pricey deals have dominated the headlines, a handful of other companies over the past year have formed more modest collaborations to see whether they can take advantage of RNAi as a therapeutic modality.

Lundbeck will use Intomics' data analysis and systems biology expertise and tools to analyze drug development data.

An artificial intelligence-based analysis suggests a third group of ancient hominins likely interbred with human ancestors, according to Popular Mechanics.

In Science this week: reduction in bee phylogenetic diversity, and more.

The New York Times Magazine looks into paleogenomics and how it is revising what's know about human history, but also possibly ignoring lessons learned by archaeologists.

The Economist reports on Synthorx's efforts to use expanded DNA bases they generated to develop a new cancer drug.